Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Ichthyosis prematurity syndrome mimics keratitis–ichthyosis–deafness syndrome at birth: Use of electron microscopy and genetic testing
Youssef, Molly J. , Wolz, Michael , Harris, Malinda N. , Richard, Gabrielle , Bridges, Alina G. , Wieland, Carilyn N. , Hand, Jennifer L. , Wolz, Michael M

International Journal of Dermatology | October 13, 2015 | Volume: 55 | Issue: 8 | Pages: No page available

10.1111/ijd.13099 | PMID 26341232 Get It

Tobacco control education in pediatric anesthesiology fellowships
Peters, Shannon M. , Pabelick, Christina M. , Warner, David O.

Pediatric Anesthesia | October 13, 2015 | Volume: 23 | Issue: 12 | Pages: 1213-1218

10.1111/pan.12277 | PMID 24383603 Get It

SummaryBackgroundCigarette smoking and secondhand smoke exposure (SHS) increase the risk of perioperative complications. Traditionally, anesthesiologists have limited involvement in tobacco control.ObjectiveTo develop and disseminate an educational curriculum that educates pediatric anesthesia fellows in tobacco control.MethodsAfter IRB approval, an online survey was disseminated to pediatric anesthesiology fellowship directors.ResultsThirty‐one surveys were completed. Most report that they ask pediatric patients about tobacco use. A majority advise their patients who smoke about the health effects of smoking, but only 40% advise children to quit, and the majority never provide educational materials to assist in smoking cessation. Half reported that they sometimes or always ask about SHS. Approximately one‐third never advise about the ill effects of SHS, nearly half never advise parents to stop smoking, and the majority never provide educational material about quitting to parents. Two‐thirds felt that it is their responsibility to advise pediatric patients not to smoke, but less than half felt the same sense of responsibility about advising parents not to smoke. Approximately two‐thirds believe that fellowship programs should provide education about the effects of smoking in the perioperative period and the effects of SHS exposure, but few programs do. Almost all would implement a free teaching module about SHS exposure and tobacco control as part of fellowship education.ConclusionsMany pediatric anesthesiology fellowship directors agree that exposure to cigarette smoke adversely impacts patients in the perioperative period, but few participate in tobacco control, and issues germane to tobacco control are not consistently addressed.
Letter: treatment of autoimmune acute liver failure - beyond consensus guidelines; author's reply
Czaja, Albert J.

Alimentary Pharmacology & Therapeutics | October 13, 2015 | Volume: 38 | Issue: 9 | Pages: 1144-1144

10.1111/apt.12498 | PMID 24099481 Get It

Gastrointestinal mucormycosis in immunocompromised hosts
Dioverti, M. Veronica , Abidi, Maheen Z. , Sohail, M. Rizwan , Walker, Randall C., Osmon, Douglas R. , Cawcutt, Kelly A., Cawcutt, Kelly , Sohail, M Rizwan , Abidi, Maheen Z , Dioverti, Maria Veronica , Abidi, Maheen Z

Mycoses | October 12, 2015 | Volume: 58 | Issue: 12 | Pages: 714-718

10.1111/myc.12419 | PMID 26456920 Get It

SummaryInvasive mucormycosis is a rare fungal infection in immunocompromised hosts, but it carries a high mortality rate. Primary gastrointestinal disease is the least frequent form of presentation. Early diagnosis and treatment are critical in the management; however, symptoms are typically non‐specific in gastrointestinal disease, leading to delayed therapy. To describe the clinical presentation, diagnosis, treatment and outcomes of gastrointestinal mucormycosis in immunocompromised hosts, we reviewed all cases of primary gastrointestinal mucormycosis in immunocompromised hosts reported in English literature as well as in our Institution from January 1st 1991 to December 31st 2013 for a total of 31 patients. About 52% of patients underwent solid organ transplant (SOT), while the rest had an underlying haematologic malignancy. Abdominal pain was the most common presenting symptom, followed by gastrointestinal bleeding and fever. Gastric disease was more common in SOT, whereas those with haematologic malignancy presented with intestinal disease (P = 0.002). Although gastrointestinal mucormycosis remains an uncommon condition in immunocompromised hosts, it carries significant morbidity and mortality, particularly in cases with intestinal involvement. A high index of suspicion is of utmost importance to institute early and appropriate therapy and improve outcomes.
Tyrosine kinase inhibitors as a first‐line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed‐treatment comparison
Firwana, Belal , Sonbol, Mohamad Bassam , Diab, Maria , Hasan, Rim, Zarzour, Ahmad, Garipalli, Archana, Doll, Donald C., Murad, M. Hassan , Al‐Kali, Aref , Raza, Shahzad , Yousef, Ibrahim M. , Murad, M Hassan , Sonbol, Mohamad B

International Journal of Cancer | October 12, 2015 | Volume: 138 | Issue: 6 | Pages: 1545-1553

10.1002/ijc.29889 | PMID 26455714 Get It

Tyrosine kinase inhibitors (TKI) are the initial treatment for majority of newly diagnosed patients with chronic myelogenous leukemia (CML) in chronic phase (CP) and are associated with marked improvement in hematological, cytogenetic, molecular response and survival rates compared with other therapies. In this review, we summarize the evidence of TKI efficacy for patients with newly diagnosed CP‐CML. Six trials at low risk of bias evaluating TKIs as an initial treatment in adults with newly diagnosed CP‐CML and enrolling 2,456 patients were included. Follow‐up times ranged from a median of 3 months to 5 years. Direct comparison showed statistically higher rates of major molecular response (MMR ≤ 0.1%IS) achievement with second‐generation TKIs at 12 months which was sustained throughout treatment period. Bayesian mixed‐treatment comparison (MTC) analysis demonstrated superiority of both nilotinib and dasatinib over imatinib in terms of efficacy. Nilotinib was associated with higher deeper molecular responses (MR4.5 ≤ 0.0032%IS) at 60 months than dasatinib but no difference in MMR. The differences between nilotinib and dasatinib are likely clinically trivial. Among TKIs, nilotinib was found to have the best survival profile. Both nilotinib and dasatinib are associated with significantly better MMR compared to imatinib that is sustained over 60 months. This analysis shows that new‐generation TKIs are not only showing faster response but also maintaining a more potent one through longer follow‐up period. It is important to note out that MTC is not a substitute for well‐conducted RCTs investigating direct comparisons.
Human leukocyte antigen and risk of disseminated histoplasmosis in solid organ transplant recipients
Zimmer, Andrea , Miller, G G, Mallal, S. , Thomas, Lora D.

Transplant Infectious Disease | October 12, 2015 | Volume: 18 | Issue: 1 | Pages: 160-161

10.1111/tid.12470 | PMID 26455591 Get It

Mechanism Responsible for T-Cell Antigen Receptor- and CD28- or Interleukin 1 (IL-1) Receptor-Initiated Regulation of IL-2 Gene Expression by NF-κB
Kalli, Kimberly R., Huntoon, Catherine J., Bell, Michael V., McKean, D J

Molecular and Cellular Biology | October 10, 2015 | Volume: 18 | Issue: 6 | Pages: 3140-3148

10.1128/mcb.18.6.3140 | PMID 9584155 Get It

Evidence for Direct Physical Association between a K+Channel (Kir6.2) and an ATP-Binding Cassette Protein (SUR1) Which Affects Cellular Distribution and Kinetic Behavior of an ATP-Sensitive K+ Channel
Alekseev, Alexey E., Krapivinsky, Grigory, Carrasco, Antonio J., Clapham, David E. , Lorenz, Eva , Carrasco, Antonio J., Terzic, André

Molecular and Cellular Biology | October 10, 2015 | Volume: 18 | Issue: 3 | Pages: 1652-1659

10.1128/mcb.18.3.1652 | PMID 9488482 Get It

Genetic Evidence for Differential Coupling of Syk Family Kinases to the T-Cell Receptor: Reconstitution Studies in a ZAP-70-Deficient Jurkat T-Cell Line
Williams, Brandi L., Schreiber, Kathy L., Zhang, Weiguo , Wange, Ronald L. , Samelson, Lawrence E. , Leibson, Paul J., Abraham, Robert T.

Molecular and Cellular Biology | October 10, 2015 | Volume: 18 | Issue: 3 | Pages: 1388-1399

10.1128/mcb.18.3.1388 | PMID 9488454 Get It